340B Drug Pricing Program
Congress should enact policies to strengthen the health care workforce and reject harmful proposals that would cut Medicare or Medicaid payments to hospitals and reduce access to care and services for patients.
AHA is pleased to support the Preserving Rules Ordered for The Entities Covered Through (PROTECT) 340B Act of 2023.
The House Energy and Commerce Subcommittee on Health is expected to hold a follow-up hearing on transparency and competition in health care. The AHA appreciates your outreach in advance of the March 28 hearing; however, based on the comments representatives made during the recent hearing, it is…
Discover how the ASAP 340B coalition's policy proposals contradict Congress' intent to preserve the 340B program. Patients' lives are at stake.
Ensuring the Protection of the Vital 340B Program for Patients and Providers
Once again, the Pharmaceutical Research and Manufacturers of America (PhRMA) has demonstrated its willingness to put the profits of its drug company members over the needs of America’s patients.
AHA Statement before the House Committee on Energy and Commerce Subcommittee on Health regarding Lowering Unaffordable Costs: Examining Transparency and Competition in Health Care.
Deceptively branded as an effort to save the 340B program, a legislative campaign by the Pharmaceutical Research and Manufacturers of America, National Association of Community Health Centers and other groups to remove many hospitals, eligible drugs and patients from the 340B program “would only…
Deceptively branded as an effort to save the 340B program, a legislative campaign by the Pharmaceutical Research and Manufacturers of America, National Association of Community Health Centers and other groups to remove many hospitals, eligible drugs and patients from the 340B program “would only…
Hospital and pharmacist advocates for safety-net health care and affordable prescription drugs are united in their firm opposition to a misguided effort by the drug industry and some community health centers that would restrict access to the 340B drug pricing program.